Leveraging ON24, CSL Behring scaled their
global healthcare professional (HCP) education, improving
data-driven insights through digital engagement
In 2023, the life sciences industry experienced a 13%
year-over-year increase in digital experiences, outpacing the
global average by 5 percentage points, according to the 2024 Life
Sciences Digital Engagement Benchmarks Report. This growth reflects
the life sciences industry's increasing focus on omnichannel
strategies to engage healthcare professionals (HCPs). Today, ON24
(NYSE: ONTF), a leading intelligent engagement platform, announced
that CSL Behring, a global leader in biotherapeutics, has scaled
its global HCP program with the ON24 platform, resulting in new
potential customers and a better understanding of customer content
engagement.
CSL Behring is a global leader in the field of biotherapeutics,
driven by its promise to save lives. The team needed to deliver a
consistent experience for HCPs — at scale — while capturing
actionable customer insights that were integrated with Veeva CRM to
make informed decisions across the organization. CSL Behring knew
that customers wanted to attend virtual and/or live events, but not
all affiliates had a suitable platform to conduct them.
“ON24 has helped us reach a thousand HCPs and attracted hundreds
of new potential customers to our programs. It truly helps our
business,” said Stuart Davis, Director, Commercial Enablement,
Marketing, CSL Behring. “The ability to create on-demand webinars
has allowed us to increase customer engagement, implementing an
always-on engagement strategy has helped increase our reach and
engage HCPs across the globe.”
Before partnering with ON24, CSL Behring faced challenges with
disjointed digital engagement tools, which didn’t integrate with
their CRM or offer comprehensive first-party engagement data.
Manual processes slowed scalability and the team was unable to
provide consistent, meaningful content to its HCP audience. By
leveraging the ON24 Intelligent Engagement Platform solutions —
from interactive content hubs to on-demand webinars — CSL Behring
can deliver content at scale but also capture and analyze audience
behavior in real-time.
Now, CSL Behring runs an integrated education program for its
HCPs, with both live and on-demand options. By streamlining event
creation and enabling affiliates to repurpose content across 40
countries, CSL Behring has increased the reach of its program
without adding headcount. The ON24 integration with Veeva CRM
ensures that the HCP first-party engagement data flows directly to
CSL Behring customer facing teams, informing follow-up strategies
and deepening customer relationships.
"Life sciences companies operate in a highly regulated
environment, where maintaining compliance while adapting to
evolving patient and provider needs is crucial," said Callan Young,
CMO of ON24. "We’re proud to support CSL Behring in their mission
to deliver life-saving therapies by helping them enhance healthcare
professional education and drive sustainable growth through
personalized, data-driven digital experiences."
Learn more about how CSL Behring transformed its HCP engagement
program powered by ON24 by reading the full case study here.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by our
promise to save lives. Focused on serving patients' needs by using
the latest technologies, we discover, develop and deliver
innovative therapies for people living with conditions in the
immunology, hematology, cardiovascular and metabolic, respiratory,
and transplant therapeutic areas. We use three strategic scientific
platforms of plasma fractionation, recombinant protein technology,
and cell and gene therapy to support continued innovation and
continually refine ways in which products can address unmet medical
needs and help patients lead full lives.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. Our parent company, CSL (ASX:CSL;
USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000
people, and delivers its lifesaving therapies to people in more
than 100 countries. For inspiring stories about the promise of
biotechnology, visit CSLBehring.com/Vita and follow us on
Twitter.com/CSLBehring.
About ON24
ON24 is on a mission to help businesses bring their go-to-market
strategy into the AI era and drive cost-effective revenue growth.
Through its leading intelligent engagement platform, ON24 enables
customers to combine best-in-class experiences with personalization
and content, to capture and act on connected insights at scale.
ON24 provides industry-leading companies, including 4 of the 5
largest global software companies, 3 of the 5 top global asset
management firms, 3 of the 5 largest global healthcare companies
and 3 of the 5 largest global industrial companies, with a valuable
source of first-party data to drive sales and marketing innovation,
improve efficiency and increase business results. Headquartered in
San Francisco, ON24 has offices globally in North America, EMEA and
APAC. For more information, visit www.ON24.com.
Forward-Looking Statements
This document contains “forward-looking statements” under
applicable securities laws. In some cases, such statements can be
identified by words such as: “expect,” “convert,” “believe,”
“plan,” “future,” “may,” “should,” “will,” and similar references
to future periods. Forward-looking statements include express or
implied statements regarding our ability to achieve our business
strategies, growth, or other future events or conditions. Such
statements are based on our current beliefs, expectations, and
assumptions about future events or conditions, which are subject to
inherent risks and uncertainties, including the risks and
uncertainties discussed in the filings we make from time to time
with the Securities and Exchange Commission. Actual results may
differ materially from those indicated in forward-looking
statements, and you should not place undue reliance on them. All
statements herein are based only on information currently available
to us and speak only as of the date hereof. Except as required by
law, we undertake no obligation to update any such statement.
© 2024 ON24, Inc. All rights reserved. ON24 and the ON24 logo
are trademarks owned by ON24, Inc., and are registered in the
United States Patent and Trademark Office and in other
countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241209540705/en/
Media: Gabriella Bello Kose press@on24.com
Investor: Irmina Blaszczyk, The Blueshirt Group for ON24
investorrelations@on24.com
Carlisle Companies (NYSE:CSL)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Carlisle Companies (NYSE:CSL)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
